25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Marksans Pharma Limited
Buy, Hold or Sell?

Let's analyze Marksans Pharma Limited together

I guess you are interested in Marksans Pharma Limited. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Marksans Pharma Limited. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Marksans Pharma Limited

I send you an email if I find something interesting about Marksans Pharma Limited.

Quick analysis of Marksans Pharma Limited (30 sec.)










What can you expect buying and holding a share of Marksans Pharma Limited? (30 sec.)

How much money do you get?

How much money do you get?
INR0.01
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
INR38.51
Expected worth in 1 year
INR75.06
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
INR37.45
Return On Investment
20.2%

For what price can you sell your share?

Current Price per Share
INR185.15
Expected price per share
INR174.60 - INR
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

1. Valuation of Marksans Pharma Limited (5 min.)




Live pricePrice per Share (EOD)

INR185.15

Intrinsic Value Per Share

INR23.27 - INR58.32

Total Value Per Share

INR61.78 - INR96.84

2. Growth of Marksans Pharma Limited (5 min.)




Is Marksans Pharma Limited growing?

Current yearPrevious yearGrowGrow %
How rich?$207.6m$143m$64.6m31.1%

How much money is Marksans Pharma Limited making?

Current yearPrevious yearGrowGrow %
Making money$31.6m$21.9m$9.7m30.7%
Net Profit Margin14.4%12.4%--

How much money comes from the company's main activities?

3. Financial Health of Marksans Pharma Limited (5 min.)




4. Comparing to competitors in the Drug Manufacturers - Major industry (5 min.)




  Industry Rankings (Drug Manufacturers - Major)  

3rd party ad coffee SUPPORTERis ad-free.

What can you expect buying and holding a share of Marksans Pharma Limited? (5 min.)

Welcome investor! Marksans Pharma Limited's management wants to use your money to grow the business. In return you get a share of Marksans Pharma Limited.

What can you expect buying and holding a share of Marksans Pharma Limited?

First you should know what it really means to hold a share of Marksans Pharma Limited. And how you can make/lose money.

Speculation

The Price per Share of Marksans Pharma Limited is INR185.15. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Marksans Pharma Limited.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Marksans Pharma Limited, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is INR38.51. Based on the TTM, the Book Value Change Per Share is INR9.14 per quarter. Based on the YOY, the Book Value Change Per Share is INR7.71 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is INR0.22 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Marksans Pharma Limited.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 INR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per Share
Usd Eps0.070.0%0.070.0%0.050.0%0.050.0%0.030.0%
Usd Book Value Change Per Share0.110.1%0.110.1%0.090.0%0.060.0%0.050.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.110.1%0.110.1%0.090.1%0.070.0%0.050.0%
Usd Price Per Share0.84-0.84-0.54-0.49-0.49-
Price to Earnings Ratio11.99-11.99-10.10-9.79-36.74-
Price-to-Total Gains Ratio7.53-7.53-5.71-7.85-74.08-
Price to Book Ratio1.83-1.83-1.55-1.69-3.30-
Price-to-Total Gains Ratio7.53-7.53-5.71-7.85-74.08-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.203285
Number of shares453
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.110.06
Usd Total Gains Per Share0.110.07
Gains per Quarter (453 shares)50.4730.64
Gains per Year (453 shares)201.88122.56
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
151971926116113
21039439412233236
31559159618349359
41978879824466482
524985100030582605
6291182120237699728
7341379140443815851
8391576160649932974
944177318085510481097
1048197020106111651220

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%10.00.00.0100.0%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%9.01.00.090.0%9.01.00.090.0%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%10.00.00.0100.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%10.00.00.0100.0%
3rd party ad coffee SUPPORTERis ad-free.

Fundamentals of Marksans Pharma Limited

About Marksans Pharma Limited

Marksans Pharma Limited, together with its subsidiaries, researches, develops, manufactures, markets, distributes, and sells generic pharmaceutical formulations in North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the analgesic, anti-inflammatory, benign prostatic hyperplasia, epilepsy, hyperparathyroidism, diabetic and antidiabetic, pain management, neurology, antacid, hormonal, antifungal, antiulcerative, cardiovascular and central nervous system, vitamin, cough and cold, dermatology, gastrointestinal, gynecology, cephalosporin, injectable, antibacterial, hypertension, oncology, and antibiotics and anti-allergic therapeutic areas. It also provides contract research and manufacturing services; and develops and out-licenses patented products. The company was incorporated in 1992 and is headquartered in Mumbai, India.

Fundamental data was last updated by Penke on 2024-07-15 03:08:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is very efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is underpriced.
Based on how much money comes from the company's main activities, the company is underpriced.
3rd party ad coffee SUPPORTERis ad-free.

1.1. Profitability of Marksans Pharma Limited.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit¬†Marksans Pharma Limited earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compare¬†Marksans Pharma Limited to the¬†Drug Manufacturers - Major industry mean.
  • A Net Profit Margin of 14.4%¬†means that¬†₹0.14 for each ₹1¬†in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Marksans Pharma Limited:

  • The MRQ is 14.4%. The company is making a huge profit. +2
  • The TTM is 14.4%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ14.4%TTM14.4%0.0%
TTM14.4%YOY12.4%+2.0%
TTM14.4%5Y12.4%+2.0%
5Y12.4%10Y10.1%+2.3%
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ14.4%10.6%+3.8%
TTM14.4%10.6%+3.8%
YOY12.4%13.3%-0.9%
5Y12.4%10.2%+2.2%
10Y10.1%10.1%0.0%
1.1.2. Return on Assets

Shows how efficient Marksans Pharma Limited is using its assets to generate profit.

  • Above 5% is considered healthy¬†but always compare¬†Marksans Pharma Limited to the¬†Drug Manufacturers - Major industry mean.
  • 12.2% Return on Assets means that¬†Marksans Pharma Limited generated¬†₹0.12 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Marksans Pharma Limited:

  • The MRQ is 12.2%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 12.2%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ12.2%TTM12.2%0.0%
TTM12.2%YOY11.3%+0.9%
TTM12.2%5Y13.0%-0.9%
5Y13.0%10Y11.3%+1.8%
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ12.2%8.3%+3.9%
TTM12.2%8.3%+3.9%
YOY11.3%9.5%+1.8%
5Y13.0%9.7%+3.3%
10Y11.3%8.3%+3.0%
1.1.3. Return on Equity

Shows how efficient Marksans Pharma Limited is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare¬†Marksans Pharma Limited to the¬†Drug Manufacturers - Major industry mean.
  • 15.3% Return on Equity means Marksans Pharma Limited generated ₹0.15¬†for each¬†₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Marksans Pharma Limited:

  • The MRQ is 15.3%. Using its investors money, the company is efficient in making profit. +1
  • The TTM is 15.3%. Using its investors money, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ15.3%TTM15.3%0.0%
TTM15.3%YOY15.4%-0.1%
TTM15.3%5Y17.9%-2.7%
5Y17.9%10Y20.2%-2.3%
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ15.3%12.6%+2.7%
TTM15.3%12.6%+2.7%
YOY15.4%12.3%+3.1%
5Y17.9%16.3%+1.6%
10Y20.2%13.7%+6.5%
3rd party ad coffee SUPPORTERis ad-free.

1.2. Operating Efficiency of Marksans Pharma Limited.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Marksans Pharma Limited is operating .

  • Measures how much profit Marksans Pharma Limited makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare¬†Marksans Pharma Limited to the¬†Drug Manufacturers - Major industry mean.
  • An Operating Margin of 0.0%¬†means the company generated ₹0.00 ¬†for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Marksans Pharma Limited:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y6.0%-6.0%
5Y6.0%10Y8.7%-2.7%
1.2.2. Operating Ratio

Measures how efficient Marksans Pharma Limited is keeping operating costs low.

  • Below 1 is considered healthy (always compare to¬†Drug Manufacturers - Major industry mean).
  • An Operation Ratio of 0.50 means that the operating costs are ₹0.50 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of Marksans Pharma Limited:

  • The MRQ is 0.497. The company is very efficient in keeping operating costs low. +2
  • The TTM is 0.497. The company is very efficient in keeping operating costs low. +2
Trends
Current periodCompared to+/- 
MRQ0.497TTM0.4970.000
TTM0.497YOY0.502-0.004
TTM0.4975Y0.842-0.344
5Y0.84210Y1.171-0.330
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4970.497+0.000
TTM0.4970.497+0.000
YOY0.5020.469+0.033
5Y0.8420.813+0.029
10Y1.1711.171+0.000
3rd party ad coffee SUPPORTERis ad-free.

1.3. Liquidity of Marksans Pharma Limited.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Marksans Pharma Limited is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to¬†Drug Manufacturers - Major industry mean).
  • A Current Ratio of 4.91¬†means the company has ₹4.91 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of Marksans Pharma Limited:

  • The MRQ is 4.913. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.913. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.913TTM4.9130.000
TTM4.913YOY3.372+1.541
TTM4.9135Y3.256+1.657
5Y3.25610Y2.444+0.812
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ4.9132.176+2.737
TTM4.9132.176+2.737
YOY3.3722.121+1.251
5Y3.2561.911+1.345
10Y2.4441.566+0.878
1.3.2. Quick Ratio

Measures if Marksans Pharma Limited is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but¬†always compare¬†Marksans Pharma Limited to the¬†Drug Manufacturers - Major industry mean.
  • A Quick Ratio of 4.30¬†means the company can pay off ₹4.30 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Marksans Pharma Limited:

  • The MRQ is 4.295. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.295. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.295TTM4.2950.000
TTM4.295YOY2.475+1.820
TTM4.2955Y2.269+2.026
5Y2.26910Y1.537+0.732
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ4.2951.584+2.711
TTM4.2951.584+2.711
YOY2.4751.767+0.708
5Y2.2691.430+0.839
10Y1.5371.030+0.507
3rd party ad coffee SUPPORTERis ad-free.

1.4. Solvency of Marksans Pharma Limited.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Marksans Pharma Limited assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare¬†Marksans Pharma Limited to Drug Manufacturers - Major industry mean.
  • A Debt to Asset Ratio of 0.20¬†means that Marksans Pharma Limited assets are¬†financed with 20.3% credit (debt) and the remaining percentage (100% - 20.3%)¬†is financed by its owners/shareholders.¬†

Let's take a look of the Debt to Asset Ratio trends of Marksans Pharma Limited:

  • The MRQ is 0.203. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.203. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.203TTM0.2030.000
TTM0.203YOY0.267-0.064
TTM0.2035Y0.273-0.070
5Y0.27310Y0.365-0.092
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2030.402-0.199
TTM0.2030.402-0.199
YOY0.2670.403-0.136
5Y0.2730.433-0.160
10Y0.3650.486-0.121
1.4.2. Debt to Equity Ratio

Measures if Marksans Pharma Limited is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but¬†always compare¬†Marksans Pharma Limited to the¬†Drug Manufacturers - Major industry mean.
  • A Debt to Equity ratio of 25.5% means that company has ₹0.26 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Marksans Pharma Limited:

  • The MRQ is 0.255. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.255. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.255TTM0.2550.000
TTM0.255YOY0.364-0.109
TTM0.2555Y0.379-0.124
5Y0.37910Y0.724-0.345
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2550.516-0.261
TTM0.2550.516-0.261
YOY0.3640.556-0.192
5Y0.3790.588-0.209
10Y0.7240.857-0.133
3rd party ad coffee SUPPORTERis ad-free.

2. Market Valuation of Marksans Pharma Limited

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures¬†how much money you pay¬†for each share for¬†every ₹1 in earnings Marksans Pharma Limited generates.

  • Above 15 is considered overpriced but¬†always compare¬†Marksans Pharma Limited to the¬†Drug Manufacturers - Major industry mean.
  • A PE ratio of 11.99 means the investor is paying ₹11.99¬†for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Marksans Pharma Limited:

  • The EOD is 31.506. Based on the earnings, the company is overpriced. -1
  • The MRQ is 11.995. Based on the earnings, the company is underpriced. +1
  • The TTM is 11.995. Based on the earnings, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD31.506MRQ11.995+19.511
MRQ11.995TTM11.9950.000
TTM11.995YOY10.102+1.893
TTM11.9955Y9.785+2.210
5Y9.78510Y36.739-26.954
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
EOD31.50619.787+11.719
MRQ11.99510.473+1.522
TTM11.99510.473+1.522
YOY10.10213.672-3.570
5Y9.7859.785+0.000
10Y36.7399.992+26.747
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Marksans Pharma Limited:

  • The EOD is 45.654. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 17.381. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is 17.381. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD45.654MRQ17.381+28.273
MRQ17.381TTM17.3810.000
TTM17.381YOY35.226-17.845
TTM17.3815Y28.646-11.265
5Y28.64610Y17.638+11.008
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
EOD45.65450.371-4.717
MRQ17.38117.381+0.000
TTM17.38117.381+0.000
YOY35.22620.356+14.870
5Y28.64614.021+14.625
10Y17.6386.307+11.331
3rd party ad coffee SUPPORTERis ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Marksans Pharma Limited is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy¬†(always compare to Drug Manufacturers - Major industry mean).
  • A PB ratio of 1.83 means the investor is paying ₹1.83¬†for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of Marksans Pharma Limited:

  • The EOD is 4.808. Based on the equity, the company is fair priced.
  • The MRQ is 1.830. Based on the equity, the company is underpriced. +1
  • The TTM is 1.830. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD4.808MRQ1.830+2.977
MRQ1.830TTM1.8300.000
TTM1.830YOY1.551+0.280
TTM1.8305Y1.691+0.139
5Y1.69110Y3.300-1.609
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
EOD4.8082.504+2.304
MRQ1.8301.350+0.480
TTM1.8301.350+0.480
YOY1.5511.439+0.112
5Y1.6911.472+0.219
10Y3.3002.335+0.965
2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Marksans Pharma Limited compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--9.1389.1380%7.715+18%5.401+69%3.851+137%
Book Value Per Share--38.51138.5110%29.373+31%23.667+63%16.441+134%
Current Ratio--4.9134.9130%3.372+46%3.256+51%2.444+101%
Debt To Asset Ratio--0.2030.2030%0.267-24%0.273-26%0.365-44%
Debt To Equity Ratio--0.2550.2550%0.364-30%0.379-33%0.724-65%
Dividend Per Share--0.2240.2240%0.259-13%0.282-21%0.264-15%
Eps--5.8775.8770%4.509+30%4.175+41%2.825+108%
Free Cash Flow Per Share--4.0564.0560%1.293+214%2.520+61%1.428+184%
Free Cash Flow To Equity Per Share--8.4218.4210%3.236+160%3.165+166%1.593+429%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--58.325--------
Intrinsic Value_10Y_min--23.270--------
Intrinsic Value_1Y_max--3.512--------
Intrinsic Value_1Y_min--2.498--------
Intrinsic Value_3Y_max--12.329--------
Intrinsic Value_3Y_min--7.406--------
Intrinsic Value_5Y_max--23.290--------
Intrinsic Value_5Y_min--12.168--------
Market Cap75784484137.600+58%31943512737.50031943512737.5000%18644251971.200+71%17378783017.900+84%17309544011.990+85%
Net Profit Margin--0.1440.1440%0.124+16%0.124+16%0.101+43%
Operating Margin----0%-0%0.060-100%0.087-100%
Operating Ratio--0.4970.4970%0.502-1%0.842-41%1.171-58%
Pb Ratio4.808+62%1.8301.8300%1.551+18%1.691+8%3.300-45%
Pe Ratio31.506+62%11.99511.9950%10.102+19%9.785+23%36.739-67%
Price Per Share185.150+62%70.49070.4900%45.550+55%40.948+72%41.534+70%
Price To Free Cash Flow Ratio45.654+62%17.38117.3810%35.226-51%28.646-39%17.638-1%
Price To Total Gains Ratio19.776+62%7.5297.5290%5.713+32%7.854-4%74.083-90%
Quick Ratio--4.2954.2950%2.475+74%2.269+89%1.537+179%
Return On Assets--0.1220.1220%0.113+8%0.130-7%0.113+8%
Return On Equity--0.1530.1530%0.154-1%0.179-15%0.202-24%
Total Gains Per Share--9.3629.3620%7.973+17%5.684+65%4.115+127%
Usd Book Value--207674278.000207674278.0000%143070130.000+45%119295679.966+74%82089641.067+153%
Usd Book Value Change Per Share--0.1090.1090%0.092+18%0.064+69%0.046+137%
Usd Book Value Per Share--0.4580.4580%0.350+31%0.282+63%0.196+134%
Usd Dividend Per Share--0.0030.0030%0.003-13%0.003-21%0.003-15%
Usd Eps--0.0700.0700%0.054+30%0.050+41%0.034+108%
Usd Free Cash Flow--21869939.00021869939.0000%6298313.000+247%12699448.450+72%7169092.141+205%
Usd Free Cash Flow Per Share--0.0480.0480%0.015+214%0.030+61%0.017+184%
Usd Free Cash Flow To Equity Per Share--0.1000.1000%0.039+160%0.038+166%0.019+429%
Usd Market Cap901835361.237+58%380127801.576380127801.5760%221866598.457+71%206807517.913+84%205983573.743+85%
Usd Price Per Share2.203+62%0.8390.8390%0.542+55%0.487+72%0.494+70%
Usd Profit--31690652.00031690652.0000%21963711.000+44%20951057.438+51%14064500.927+125%
Usd Revenue--220404541.000220404541.0000%177409841.000+24%163111825.138+35%129154294.731+71%
Usd Total Gains Per Share--0.1110.1110%0.095+17%0.068+65%0.049+127%
 EOD+4 -4MRQTTM+0 -0YOY+28 -65Y+26 -910Y+29 -6

3.2. Fundamental Score

Let's check the fundamental score of Marksans Pharma Limited based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1531.506
Price to Book Ratio (EOD)Between0-14.808
Net Profit Margin (MRQ)Greater than00.144
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than14.295
Current Ratio (MRQ)Greater than14.913
Debt to Asset Ratio (MRQ)Less than10.203
Debt to Equity Ratio (MRQ)Less than10.255
Return on Equity (MRQ)Greater than0.150.153
Return on Assets (MRQ)Greater than0.050.122
Total7/10 (70.0%)

3.3. Technical Score

Let's check the technical score of Marksans Pharma Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5062.664
Ma 20Greater thanMa 50175.803
Ma 50Greater thanMa 100165.564
Ma 100Greater thanMa 200161.336
OpenGreater thanClose187.800
Total5/5 (100.0%)



Latest Balance Sheet

Balance Sheet of 2023-03-31. Currency in INR. All numbers in thousands.

Summary
Total Assets21,903,890
Total Liabilities4,452,270
Total Stockholder Equity17,451,620
 As reported
Total Liabilities 4,452,270
Total Stockholder Equity+ 17,451,620
Total Assets = 21,903,890

Assets

Total Assets21,903,890
Total Current Assets16,753,010
Long-term Assets0
Total Current Assets
Cash And Cash Equivalents 875,230
Short-term Investments 3,326,470
Net Receivables 4,168,460
Inventory 4,847,390
Other Current Assets 361,910
Total Current Assets  (as reported)16,753,010
Total Current Assets  (calculated)13,579,460
+/- 3,173,550
Long-term Assets
Property Plant Equipment 3,868,890
Goodwill 384,890
Intangible Assets 707,970
Long-term Assets  (as reported)0
Long-term Assets  (calculated)4,961,750
+/- 4,961,750

Liabilities & Shareholders' Equity

Total Current Liabilities3,409,900
Long-term Liabilities0
Total Stockholder Equity17,451,620
Total Current Liabilities
Short-term Debt 415,880
Total Current Liabilities  (as reported)3,409,900
Total Current Liabilities  (calculated)415,880
+/- 2,994,020
Long-term Liabilities
Long term Debt Total 656,890
Capital Lease Obligations Min Short Term Debt-415,880
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)241,010
+/- 241,010
Total Stockholder Equity
Common Stock453,160
Retained Earnings 11,054,990
Capital Surplus 5,044,980
Other Stockholders Equity 898,490
Total Stockholder Equity (as reported)17,451,620
Total Stockholder Equity (calculated)17,451,620
+/-0
Other
Cash And Equivalents2,949,140
Cash and Short Term Investments 7,150,840
Common Stock Shares Outstanding 453,164
Liabilities and Stockholders Equity 21,903,890
Net Working Capital 13,343,110



Balance Sheet

Currency in INR. All numbers in thousands.

 Trend2023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-312016-03-312015-03-312014-03-31
> Total Assets 
4,900,953
6,755,546
7,199,981
7,518,058
7,321,852
8,037,084
8,968,401
12,282,511
16,401,000
21,903,890
21,903,89016,401,00012,282,5118,968,4018,037,0847,321,8527,518,0587,199,9816,755,5464,900,953
   > Total Current Assets 
3,429,451
5,088,315
4,402,419
4,838,826
4,505,367
5,314,419
5,901,874
9,022,513
12,012,000
16,753,010
16,753,01012,012,0009,022,5135,901,8745,314,4194,505,3674,838,8264,402,4195,088,3153,429,451
       Cash And Cash Equivalents 
469,470
1,852,652
353,013
250,494
397,166
328,550
937,271
515,988
1,566,860
875,230
875,2301,566,860515,988937,271328,550397,166250,494353,0131,852,652469,470
       Short-term Investments 
0
0
0
0
0
0
0
1,577,816
1,402,870
3,326,470
3,326,4701,402,8701,577,8160000000
       Net Receivables 
1,696,072
1,834,544
2,172,930
2,475,811
1,769,056
1,765,969
2,433,517
2,713,813
3,947,780
4,168,460
4,168,4603,947,7802,713,8132,433,5171,765,9691,769,0562,475,8112,172,9301,834,5441,696,072
       Inventory 
1,025,887
1,301,068
1,677,917
1,900,870
2,181,241
2,932,461
2,418,439
4,043,197
4,244,420
4,847,390
4,847,3904,244,4204,043,1972,418,4392,932,4612,181,2411,900,8701,677,9171,301,0681,025,887
       Other Current Assets 
238,021
100,051
3,772
2,024
100,980
217,212
110,601
171,700
322,320
361,910
361,910322,320171,700110,601217,212100,9802,0243,772100,051238,021
   > Long-term Assets 
0
0
0
2,684,683
2,801,941
2,722,664
3,066,528
0
0
0
0003,066,5282,722,6642,801,9412,684,683000
       Property Plant Equipment 
724,825
1,023,705
1,641,388
1,648,624
1,863,685
1,980,821
2,200,764
2,540,209
3,422,870
3,868,890
3,868,8903,422,8702,540,2092,200,7641,980,8211,863,6851,648,6241,641,3881,023,705724,825
       Goodwill 
311,178
282,927
779,015
696,829
617,487
314,499
243,758
195,862
300,250
384,890
384,890300,250195,862243,758314,499617,487696,829779,015282,927311,178
       Intangible Assets 
420,493
352,344
276,142
327,898
312,603
401,943
826,398
474,357
585,690
707,970
707,970585,690474,357826,398401,943312,603327,898276,142352,344420,493
> Total Liabilities 
3,412,773
2,876,906
2,751,115
3,183,734
2,613,206
2,612,260
2,608,259
3,417,561
4,378,300
4,452,270
4,452,2704,378,3003,417,5612,608,2592,612,2602,613,2063,183,7342,751,1152,876,9063,412,773
   > Total Current Liabilities 
3,191,194
2,862,355
2,511,203
2,960,583
2,346,796
2,326,242
2,196,858
2,983,994
3,562,180
3,409,900
3,409,9003,562,1802,983,9942,196,8582,326,2422,346,7962,960,5832,511,2032,862,3553,191,194
       Short-term Debt 
2,219,326
1,220,113
878,929
1,097,103
1,174,132
999,087
188,425
187,400
412,920
415,880
415,880412,920187,400188,425999,0871,174,1321,097,103878,9291,220,1132,219,326
       Short Long Term Debt 
2,219,326
1,220,113
884,812
1,097,103
1,179,621
1,002,165
188,884
0
0
0
000188,8841,002,1651,179,6211,097,103884,8121,220,1132,219,326
       Accounts payable 
831,818
1,070,195
1,189,802
1,617,841
674,806
1,060,692
1,045,010
0
0
0
0001,045,0101,060,692674,8061,617,8411,189,8021,070,195831,818
       Other Current Liabilities 
301,293
523,437
464,946
5,993
5,828
132,602
885,076
0
0
0
000885,076132,6025,8285,993464,946523,437301,293
   > Long-term Liabilities 
0
0
0
0
156,371
183,850
280,300
0
0
0
000280,300183,850156,3710000
       Long term Debt Total 
0
0
125,000
110,000
100,000
100,000
50,000
143,257
414,340
656,890
656,890414,340143,25750,000100,000100,000110,000125,00000
       Capital Lease Obligations 
0
0
0
0
0
0
107,615
0
0
0
000107,615000000
> Total Stockholder Equity
1,286,824
3,672,639
4,448,865
4,334,325
4,708,646
5,424,823
6,360,143
8,864,950
12,022,700
17,451,620
17,451,62012,022,7008,864,9506,360,1435,424,8234,708,6464,334,3254,448,8653,672,6391,286,824
   Common Stock
385,307
409,314
409,314
409,314
409,314
409,314
409,314
409,314
409,310
453,160
453,160409,310409,314409,314409,314409,314409,314409,314409,314385,307
   Retained Earnings 
518,755
1,611,772
2,258,024
2,175,794
2,481,786
3,202,272
5,950,829
6,571,749
9,246,580
11,054,990
11,054,9909,246,5806,571,7495,950,8293,202,2722,481,7862,175,7942,258,0241,611,772518,755
   Accumulated Other Comprehensive Income 0000000000
   Capital Surplus 
0
0
1,751,317
1,751,317
1,751,317
1,751,317
1,751,317
1,751,317
1,731,870
5,044,980
5,044,9801,731,8701,751,3171,751,3171,751,3171,751,3171,751,3171,751,31700
   Treasury Stock0000000000



Balance Sheet

Currency in INR. All numbers in thousands.




Cash Flow

Currency in INR. All numbers in thousands.




Income Statement

Currency in INR. All numbers in thousands.


Latest Income Statement (annual, 2023-03-31)

Gross Profit (+$)
totalRevenue18,521,390
Cost of Revenue-9,213,580
Gross Profit9,307,8109,307,810
 
Operating Income (+$)
Gross Profit9,307,810
Operating Expense-0
Operating Income2,985,4009,307,810
 
Operating Expense (+$)
Research Development0
Selling General Administrative4,541,110
Selling And Marketing Expenses0
Operating Expense04,541,110
 
Net Interest Income (+$)
Interest Income349,160
Interest Expense-0
Other Finance Cost-349,160
Net Interest Income0
 
Pretax Income (+$)
Operating Income2,985,400
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)3,376,5302,985,400
EBIT - interestExpense = 0
2,663,080
2,663,080
Interest Expense0
Earnings Before Interest and Taxes (EBIT)03,376,530
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax3,376,530
Tax Provision-723,320
Net Income From Continuing Ops02,653,210
Net Income2,663,080
Net Income Applicable To Common Shares2,663,080
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net00
 

Technical Analysis of Marksans Pharma Limited
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Marksans Pharma Limited. The general trend of Marksans Pharma Limited is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Marksans Pharma Limited's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Marksans Pharma Limited.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: .

The bearish price targets are: 185.40 > 179.10 > 174.60.

Tweet this
Marksans Pharma Limited Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging¬†trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Marksans Pharma Limited. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Marksans Pharma Limited Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a¬†lagging momentum¬†indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Marksans Pharma Limited. The current macd is 7.62619703.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Marksans Pharma Limited price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Marksans Pharma Limited. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Marksans Pharma Limited price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Marksans Pharma Limited Daily Moving Average Convergence/Divergence (MACD) ChartMarksans Pharma Limited Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Marksans Pharma Limited. The current adx is 33.15.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Marksans Pharma Limited shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Marksans Pharma Limited Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows¬†the current trend.
  • Shows¬†potential entry signals.
  • Shows¬†¬†potential exit signals.
  • Can be used to place¬†trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Marksans Pharma Limited. The current sar is 197.25.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Marksans Pharma Limited Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum¬†indicator, meaning the signals are instant.
  • Ranges¬†between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Marksans Pharma Limited. The current rsi is 62.66. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
Marksans Pharma Limited Daily Relative Strength Index (RSI) ChartMarksans Pharma Limited Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading¬†momentum¬†indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges¬†between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Marksans Pharma Limited. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Marksans Pharma Limited price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Marksans Pharma Limited Daily Stochastic Oscillator ChartMarksans Pharma Limited Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,¬†the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Marksans Pharma Limited. The current cci is 57.02.

Marksans Pharma Limited Daily Commodity Channel Index (CCI) ChartMarksans Pharma Limited Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Marksans Pharma Limited. The current cmo is 21.97.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Marksans Pharma Limited Daily Chande Momentum Oscillator (CMO) ChartMarksans Pharma Limited Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and¬†-100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Marksans Pharma Limited. The current willr is -32.39625167.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Marksans Pharma Limited is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Marksans Pharma Limited Daily Williams %R ChartMarksans Pharma Limited Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold¬†

Score

Let's take a look at the Bollinger Bands of Marksans Pharma Limited.

Marksans Pharma Limited Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Marksans Pharma Limited. The current atr is 7.96369388.

Marksans Pharma Limited Daily Average True Range (ATR) ChartMarksans Pharma Limited Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Marksans Pharma Limited. The current obv is 26,126,925.

Marksans Pharma Limited Daily On-Balance Volume (OBV) ChartMarksans Pharma Limited Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Marksans Pharma Limited. The current mfi is 80.39.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
Marksans Pharma Limited Daily Money Flow Index (MFI) ChartMarksans Pharma Limited Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Marksans Pharma Limited.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-02-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-06CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-12BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-01CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-05-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-05-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-05-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-05-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-05-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-05-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-05-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-05-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-05-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-06-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-10CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-06-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-06-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-06-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-06-14MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-06-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-20STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-06-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-06-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-05STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-07-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-11STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-15RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-07-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-19STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Marksans Pharma Limited Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Marksans Pharma Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5062.664
Ma 20Greater thanMa 50175.803
Ma 50Greater thanMa 100165.564
Ma 100Greater thanMa 200161.336
OpenGreater thanClose187.800
Total5/5 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Marksans Pharma Limited with someone you think should read this too:
  • Are you bullish or bearish on Marksans Pharma Limited? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Marksans Pharma Limited? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Marksans Pharma Limited

I send you an email if I find something interesting about Marksans Pharma Limited.


Comments

How you think about this?

Leave a comment

Stay informed about Marksans Pharma Limited.

Receive notifications about Marksans Pharma Limited in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.